Last reviewed · How we verify
Vaginal micronized progesterone
Micronized progesterone administered vaginally binds to progesterone receptors to support luteal phase function and maintain early pregnancy.
Micronized progesterone administered vaginally binds to progesterone receptors to support luteal phase function and maintain early pregnancy. Used for Luteal phase support in assisted reproductive technology (ART), Early pregnancy support and miscarriage prevention.
At a glance
| Generic name | Vaginal micronized progesterone |
|---|---|
| Also known as | Cyclogest® 400 mg |
| Sponsor | Instituto Valenciano de Infertilidade de Lisboa |
| Drug class | Progestin |
| Target | Progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive/Fertility |
| Phase | FDA-approved |
Mechanism of action
Progesterone is a steroid hormone that acts on nuclear progesterone receptors in the endometrium and reproductive tract to promote secretory changes, suppress uterine contractions, and support implantation and early pregnancy maintenance. Micronization increases bioavailability and vaginal absorption, allowing direct delivery to reproductive tissues while minimizing systemic metabolism.
Approved indications
- Luteal phase support in assisted reproductive technology (ART)
- Early pregnancy support and miscarriage prevention
Common side effects
- Vaginal irritation or discharge
- Headache
- Breast tenderness
- Bloating
Key clinical trials
- Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (NA)
- Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency (PHASE3)
- Exogenous Progesterone as Ovulation Trigger (PHASE4)
- A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix (PHASE3)
- Comparison of Two Vaginal Progesterone Forms in Frozen Embryo Transfer
- Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth (PHASE4)
- Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer
- Cerclage Plus Progesterone vs Progesterone Alone in Twin Short Cervix (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: